. home.aspx

NEWS

home.aspx
   


Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

October 01, 2020 / Prnewswire
SHARESHARESHARE

Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and development of innovative therapeutics across a range of up to 20 diseases. The collaboration is expected to play an important role in allowing Ionis to continue delivering transformational medicines to patients for many years to come. Genuity Science's approach combines high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis' proprietary antisense technology, has the potential to significantly expedite the drug development process through a more direct translation of targets into therapeutics.